title: Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.
abstract: OBJECTIVE
  The aim of this study was to assess the efficacy and safety of long-term treatment with two different antimuscarinics, imidafenacin and solifenacin, in patients with overactive bladder (OAB).
  
  
  METHODS
  Male or female patients 20 years of age or older who had urgency (more than 1 episode in 24 h) were randomized into two groups: group I, imidafenacin (0.1 mg twice daily), and group S, solifenacin (5 mg once daily) for a 12-month treatment regimen. Subjective and objective symptoms were assessed before, and 1, 3, 6 and 12 months after treatment.
  
  
  RESULTS
  A total of 109 patients, including 55 (mean age: 72.0 years) in group I and 54 (mean age: 70.4 years) in group S, were treated. Subjective symptoms were significantly improved in group I and S after treatment. Dry mouth significantly worsened in both groups. However, the duration of dry mouth in group I was significantly shorter than that in group S. Three (5.8%) and 7 (13.5%) patients discontinued treatment due to adverse events in group I and group S, respectively.
  
  
  CONCLUSIONS
  Imidafenacin and solifenacin were efficacious, safe, and well-tolerated treatments for OAB. As for adverse events, group I had fewer than group S.
authors.affiliation: Department of Urology, Kawasaki Medical School, Kurashiki, Japan. uroyoko @ med.kawasaki-m.ac.jp
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Takao
authors.initials: T
authors.lastname: Koide
authors.forename: Ryoei
authors.initials: R
authors.lastname: Hara
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fukumoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Miyaji
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagai
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011446:Prospective Studies; D011812:Quinuclidines / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014987:Xerostomia / Q000139:chemically induced
chemical_list: D007093:Imidazoles; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate; C120953:imidafenacin